The World Economic Forum has named Berkeley Lab startup Second Genome one of its Technology Pioneers for 2017. WEF’s Technology Pioneers are early stage companies anticipated to have a significant effect on business and society. Second Genome, based in South San Francisco, applies its proprietary microbiome platform to drug discovery and development. The startup’s current focus is the treatment of inflammatory bowel disease (IBD).